Summary

Dr. Agarwal's Health Care Limited announced strong financial performance for FY2026, with total income soaring by 20.9% year-over-year to ₹2,125 Crores. The company demonstrated significant profitability improvement, with Profit After Tax (PAT) growing by 52.4% to ₹168 Crores and IND-AS EBITDA increasing by 22.2% to ₹614 Crores for the fiscal year. The fourth quarter of FY2026 also showed robust growth, with total income at ₹577 Crores, up 21.2% YoY, and revenue from operations rising by 22.6% to ₹564 Cr. Furthermore, the company expanded its operational footprint, adding 19 new centers in Q4 FY2026, and reallocated unspent IPO proceeds to bolster its liquidity for future growth and contingencies.

Key Highlights

1. 1

   Dr. Agarwal's Health Care Limited reported a significant increase in total income for FY2026, which soared by 20.9% year-over-year to ₹2,125 Crores.

2. 2

   Profit After Tax (PAT) for FY2026 saw a robust growth of 52.4% year-over-year, reaching ₹168 Crores.

3. 3

   The company's IND-AS EBITDA for fiscal year 2026 grew by 22.2% year-over-year, amounting to ₹614 Crores.

4. 4

   For the fourth quarter of FY2026, total income stood at ₹577 Crores, representing a 21.2% increase year-over-year.

5. 5

   Revenue from operations in Q4 FY2026 climbed by 22.6% year-over-year to ₹564 Cr, with India operations contributing ₹505 Cr, up 22.1% YoY.

6. 6

   The company expanded its network to 288 facilities by March 31, 2026, adding 19 new centers during Q4 FY2026, and performed 84,962 surgeries, marking a 23.6% YoY growth.

7. 7

   The Board approved the reallocation of ₹14.884 crores of unspent IPO proceeds from 'Issue related expenses' to 'General Corporate Purposes and Unidentified Inorganic Acquisitions', enhancing the company's liquidity buffer.